Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02603159

Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy — DCECRT  

Stage III Esophageal Squamous Cell Carcinoma Clinical Trial

Clinical Trial Summary

Definitive chemoradiotherapy with cisplatin with cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer.But in China because of its toxic reaction, most of patients stop the halfway.Because low toxicity, Capecitabine is widely used in the chemotherapy of esophageal cancer.

The purpose of this experiment was to study the different cycle on capecitabine with chemotherapy for esophageal cancer chemoradiation effect.We are prepared to within 2 years study recruited 200 patients with esophageal cancer.The primary endpoint is overall survival and the secondary endpoints include progression-free survival, response rate,pathologic complete response rate and adverse events.

Clinical Trial Description

We recruited the patients who were pathologically confirmed with esophageal squamous cell carcinoma from the Oct 2014. The the patients was divided into two groups. Group 1: Capecitabine + chemoradiation, radiation at the end of the stop using capecitabine. Group 2: Capecitabine + chemoradiation, at the end of the radiotherapy with capecitabine consolidating treatment for 5 weeks. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02603159
Study type Interventional
Source The First Affiliated Hospital of Henan University of Science and Technology
Contact Shegan Gao, Doctor
Phone 18638859977
Email gsg112258@163.com
Status Recruiting
Phase Phase 3
Start date October 2014
Completion date December 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02628665 - Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Phase 3
Recruiting NCT02604615 - The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy Phase 3
Recruiting NCT02607540 - Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer Phase 3
Active, not recruiting NCT02025036 - Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer Phase 3
Completed NCT02644408 - Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy Phase 3
Recruiting NCT02812641 - Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC Phase 2
Completed NCT02459457 - A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer Phase 3